ArticleCancer science2009
Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer.
Article in Cancer science, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 51 citations in OpenAlex.
- Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.Breast cancer research and treatment · 2017Trial
- Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation.Hormones & cancer · 2011Trial
- ERK1/2-RSK2 Signaling in Regulation of ERα-Mediated Responses.Endocrinology · 2022Review
- PKNOX2 suppresses gastric cancer through the transcriptional activation of IGFBP5 and p53.Oncogene · 2019Article
- Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro.Oncotarget · 2016Article
- Tumor biology in estrogen receptor-positive, human epidermal growth factor receptor type 2-negative breast cancer: Mind the menopausal status.World journal of clinical oncology · 2015Article
- IGFBP-2 and -5: important regulators of normal and neoplastic mammary gland physiology.Journal of cell communication and signaling · 2015Article
- Article
- STAT signaling in different breast cancer sub-types.Molecular and cellular endocrinology · 2014Review
- p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.Cancer science · 2014Article
- Microbial transformation of anti-cancer steroid exemestane and cytotoxicity of its metabolites against cancer cell lines.Chemistry Central journal · 2013Article
- The role of AIB1 in breast cancer.Oncology letters · 2012Article
- Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?Nature reviews. Clinical oncology · 2012Review
- Functional roles and clinical values of insulin-like growth factor-binding protein-5 in different types of cancers.Chinese journal of cancer · 2012Review
- The Role of Androgen Receptor in Breast Cancer.Drug discovery today. Disease mechanisms · 2012Article
- A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model.Oncology · 2012Article
- Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy.British journal of cancer · 2011Article
- Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients.British journal of cancer · 2011Article
- High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer.International journal of clinical oncology · 2011Article
- Altered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial content.Molecular endocrinology (Baltimore, Md.) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endocrine therapy is the most important treatment of choice for estrogen receptor (ER)-positive breast cancer. Potential mechanisms for resistance to endocrine therapy involve ER-coregulatory proteins and cross-talk between ER and other growth factor-signaling networks. However, the factors and pathways responsible for endocrine therapy resistance, particularly resistance to aromatase inhibitors, have not been clearly established. Sixteen postmenopausal patients with ERalpha-positive primary breast cancer were treated daily with 25 mg of exemestane (an aromatase inhibitor) for 6 months. Expressions of ERalpha, ERbeta, progesterone receptor (PgR), androgen receptor (AR), amplified in breast cancer 1 (AIB1), aromatase, epidermal growth factor receptor, human epidermal growth factor receptor type 2, Ki67, cyclin D1, p53, Bcl2, signal transducer and activator of transcription 5 (Stat5), and insulin-like growth factor binding protein 5 (IGFBP5), and phosphorylations of ERalpha serine (Ser) 118, ERalpha Ser167, Akt Ser473, and p44/42 MAPK threonine (Thr) 202/tyrosine (Tyr) 204, were examined by immunohistochemistry on pretreatment tumor biopsies and post-treatment surgical specimens. Analyses were made to test for correlations with response to exemestane. Of the 16 patients, seven responded and nine retained stable disease. High-level expression of AIB1 and phosphorylation of Akt Ser473 were significantly associated with a better response to exemestane, suggesting that these factors could be considered as predictors of exemestane response. Expressions of ERalpha, ERbeta, PgR, aromatase, Ki67, cyclin D1, and p53, and phosphorylations of ERalpha Ser118, ERalpha Ser167, and p44/42 MAPK Thr202/Tyr204, were decreased, whereas expressions of Stat5 and IGFBP5 were increased in post-treatment specimens compared to the values in pretreatment biopsies. Thus, the analysis of factors involved in the estrogen-dependent growth-signaling pathways may be useful in identifying patients responsive to exemestane.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.